va-Q-tec, an innovative solutions company in the insulation sector, is expanding its global presence by opening an Indian subsidiary in Mumbai.

With the new subsidiary, the company complements its international offering with additional local sales and service capabilities. va-Q-tec also pays tribute to the fact that the country is considered one of the main producers of pharmaceutical products.

These drugs and vaccines are often temperature sensitive and therefore solutions are needed to transport the produced pharmaceuticals safely to their destination. This presents a particular challenge given India’s sometimes poorly developed logistical infrastructure and variable climatic zones. Due to their exceptional passive technology, va-Q-tec’s advanced thermal boxes and containers have been recognized for many years in the temperature-controlled supply chain market as an ideal safe and reliable solution for these types of challenges. .

India’s economy has been growing steadily for many years, but the pharmaceutical industry has taken off disproportionately as it is heavily supported by the government. The country is considered one of the world’s largest producers of pharmaceuticals, including drugs and vaccines, providing up to 60% of the global supply. The country’s pharmaceutical market reached $55 billion in 2020, with more potential and projected growth of $65-70 billion by 2024.

Thanks to the three TempChain service centers in Hyderabad and Mumbai, which have been operating there for several years, va-Q-tec’s solutions have already been used by several well-known companies. These products have repeatedly proved that special technology and sophisticated services are an important element for domestic road transport, but also for long-distance air freight transport.

The new distribution site will further support the growth of this vital industry. To this end, va-Q-tec was able to win Ravi Kumar, a recognized expert from the pharmaceutical industry. Together with the Indian team, he will cover the whole country in terms of service and advice and thus provide intensive support for a large number of projects in the Indian market.

“The new subsidiary in Mumbai is a strategically important next step in making vaccine and medicine shipments safer, more reliable and more environmentally friendly, not just locally, but globally. We are very proud to be able to respond faster and more directly to the requirements of the rapidly growing market with a dynamic local team and thus adapt our services even better to the needs of customers in India. I’m especially pleased that with Ravi Kumar as Managing Director, we can offer the focused experience of a true industry expert on-site!” said Christopher J. Storch, Global Sales Manager, va-Q Group -tec.

Modern pharmaceuticals, such as Corona mRNA vaccines, in most cases require stable temperatures in various ranges between -70°C and +8°C. This is often a major challenge, especially in a country like India, which covers a range of climates from alpine climates to the humid and hot outdoor temperatures of the tropics. Additionally, many parts of the country have poor infrastructure.